MoonLake Immunotherapeutics

Insight: CFO’s zero‑cost restricted‑stock buy after FDA feedback signals strong confidence in MoonLake’s upcoming BLA and investor day, boosting investor sentiment.

MoonLake CFO’s zero‑cost purchase of 354k restricted shares signals strong insider confidence ahead of its 2026 BLA filing, urging investors to reassess the high‑risk biotech’s value.